Value investing message boards image Log on |  Join ($$) Stock market forums image VF "How To" Guide        Welcome, guest! Learn about guest access                       
ValueForum.com Home
• Related Discussion Forum Messages
As a ValueForum member, this section would contain DVAX message board posts where the ticker symbol DVAX has been mentioned by ValueForum members in posts. Learn more about guest access, and benefits of membership -- we hope you will consider joining ValueForum or trying out our service with a 24 hour trial pass.

• Latest DVAX SEC Filings

Filings Format Description Filing Date File/Film Number
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001209191-20-032967 Size: 5 KB
2020-05-29
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001209191-20-032963 Size: 5 KB
2020-05-29
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001209191-20-032958 Size: 5 KB
2020-05-29
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001209191-20-032956 Size: 5 KB
2020-05-29
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001209191-20-032949 Size: 5 KB
2020-05-29
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0000899243-20-014556 Size: 5 KB
2020-05-29
8-K  Documents   Interactive Data Current report, items 5.02, 5.03, 5.07, and 9.01
Acc-no: 0001564590-20-027622 (34 Act)  Size: 217 KB
2020-05-29 001-34207
20927812
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0000899243-20-014431 Size: 5 KB
2020-05-28
SC 13D/A  Documents [Amend] General statement of acquisition of beneficial ownership
Acc-no: 0001193125-20-154385 (34 Act)  Size: 56 KB
2020-05-28 005-80035
20922247
DEFA14A  Documents Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Acc-no: 0001193125-20-150214 (34 Act)  Size: 20 KB
2020-05-22 001-34207
20906668
More DVAX SEC Filings


Related news from
Thu, 04 Jun 2020
22:37:50 +0000
Edited Transcript of DVAX earnings conference call or presentation 7-May-20 8:30pm GMT
Q1 2020 Dynavax Technologies Corp Earnings Call
Mon, 01 Jun 2020
20:00:00 +0000
Why Dynavax Stock Crushed It Today
Shares of Dynavax (NASDAQ: DVAX) were skyrocketing 30.2% higher as of 3:47 p.m. EDT on Monday. Investors need to be cautious about putting too much focus on the comments last week made by Sinovac researcher Luo Baishan. When asked about the prospects for the COVID-19 vaccine being developed by Sinovac using Dynavax's CpG 1018 adjuvant, Baishan replied that he was 99% sure that the vaccine would be successful.
Sat, 30 May 2020
21:12:24 +0000
Notable Insider Buys: Avis, Dynavax And Formula One
* Insider buying can be an encouraging signal for potential investors. * Beneficial owner Berkshire Hathaway made a huge purchase last week. * A director took advantage of a coronavirus vaccine contender's secondary offering.Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason -- they believe the stock price will rise and they want to profit from it. So insider buying can be an encouraging signal for potential investors, particularly during periods of uncertainty.Insiders continued to add shares despite overall market volatility and global economic gloom. Here are some of the most noteworthy insider purchases reported in the past week.Formula One Group Liberty Media Formula One (NASDAQ: FWONA) saw 10% owner Berkshire Hathaway Inc. (NYSE: BRK-A) add nearly 3.17 million shares of this motorsport company to its stake. At per-share prices ranging from $33.07 to $37.05, that totaled almost $112.42 million.Shares of this Liberty Media subsidiary popped more than 9% in last week's trading to end at $33.82 apiece, within the purchase price range above. The share price is up about 75% since its year-to-date low during the pandemic panic selling back in March. The analysts' consensus target price is up at $45.53.Avis Budget Beneficial owner SRS Investment Management purchased almost 500,000 Avis Budget Group Inc. (NASDAQ: CAR) shares of this New Jersey-based company last week. Share prices ranged from $18.57 to $20.59 apiece, and the total for these transactions was more than $9.88 million.Competitor Hertz Global recently filed for bankruptcy and will be delisted from the New York Stock Exchange. Avis shares ended last week up nearly 29% to $21.53, above the purchase prices mentioned above. The share price is more than 77% higher since its year-to-date low in March.See Also: What You Need To Know About Moderna's Insider SellingDynavax A Dynavax Technologies Corporation (NASDAQ: DVAX) director took advantage of a secondary offering last week. He indirectly bought a million shares for $5 apiece, which cost him $5 million. He is also a director at Mersana Therapeutics Inc (NASDAQ: MRSN) and bought more than 3 million of those shares back in April.Dynavax is among those companies in a race for a vaccine for COVID-19. Its shares soared more than 19% last week and closed most recently at $6.12 a share. It's now about 154% higher than the year-to-date low in March. The consensus price target is up at $16, though only two analysts were surveyed.In addition, note that there was some amount of insider buying at Green Dot Corporation (NYSE: GDOT), Jazz Pharmaceuticals PLC (NASDAQ: JAZZ) and Royal Caribbean Cruises Ltd (NYSE: RCL) last week as well.See more from Benzinga * Benzinga's Bulls And Bears Of The Week: Amazon, Disney, Netflix And More * Notable Insider Buys This Past Week: Berkshire Hathaway, Sysco And More * Barron's Picks And Pans: Dropbox, Slack, Starbucks And More(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Fri, 29 May 2020
20:29:00 +0000
Dynavax Stock Soars 26.4% Today on COVID-19 Vaccine Hopes
Shares of Dynavax Technologies (NASDAQ: DVAX) jumped 26.4% on Friday following comments by researchers at Sinovac, a Chinese drug developer that's collaborating with Dynavax on a COVID-19 vaccine. In April, Dynavax and Sinovac agreed to collaborate to develop a vaccine for COVID-19. Dynavax is contributing an adjuvant that can boost immune responses in vaccinated patients, while Sinovac is contributing an inactivated coronavirus vaccine candidate.
Fri, 29 May 2020
12:53:12 +0000
Implied Volatility Surging for Dynavax Technologies (DVAX) Stock Options
Investors need to pay close attention to Dynavax Technologies (DVAX) stock based on the movements in the options market lately.
Thu, 28 May 2020
20:05:10 +0000
Dynavax to Present at the William Blair 40th Annual Growth Stock Conference
EMERYVILLE, Calif., May 28, 2020 -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today.
Wed, 27 May 2020
20:05:10 +0000
Dynavax Technologies Announces Closing of $80.5 Million Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Dynavax Technologies Corporation (DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced the closing of its previously announced underwritten public offering of 16,100,000 shares of its common stock, including the exercise in full by the underwriters of their option to purchase an additional 2,100,000 shares, at a price to the public of $5.00 per share. The gross proceeds to Dynavax from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Dynavax, were approximately $80.5 million. Cowen, Evercore ISI and William Blair acted as joint book-running managers for the offering.
Fri, 22 May 2020
14:19:52 +0000
Price Over Earnings Overview: Dynavax Technologies
Right now, Dynavax Technologies Inc. (NASDAQ: DVAX) share price is at $5.35, after a 5.48% decrease. Over the past month, the stock went up by 57.65%, but over the past year, it actually decreased by 1.29%. With questionable short-term performance like this, and great long-term performance, long-term shareholders might want to start looking into the company's price-to-earnings ratio.The stock is currently above from its 52 week low by 197.22%. Assuming that all other factors are held constant, this could present itself as an opportunity for investors trying to diversify their portfolio with biotechnology stocks, and capitalize on the lower share price observed over the year.The P/E ratio measures the current share price to the company's earnings per share. It is used by long-term investors to analyze the company's current performance against its past earnings, historical data and aggregate market data for the industry or the indices, such as S&P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also shows that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future.Depending on the particular phase of a business cycle, some industries will perform better than others.Compared to the aggregate P/E ratio of the 1.15 in the biotechnology industry, Dynavax Technologies has a lower P/E ratio of 0.0. Shareholders might be inclined to think that they might perform worse than its industry peers. It's also possible that the stock is undervalued.price to earnings ratio is not always a great indicator of the company's performance. Depending on the earnings makeup of a company, investors may not be able to attain key insights from trailing earnings.See more from Benzinga * 20 Healthcare Stocks Moving In Friday's Pre-Market Session * Price Over Earnings Overview: Dynavax Technologies * 20 Healthcare Stocks Moving In Thursday's Pre-Market Session(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Fri, 22 May 2020
01:00:10 +0000
Dynavax Technologies Announces Pricing of $70.0 Million Public Offering of Common Stock
Dynavax Technologies Corporation (DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced the pricing of its previously announced underwritten public offering of 14,000,000 shares of its common stock at a price to the public of $5.00 per share. The gross proceeds to Dynavax from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Dynavax, are expected to be approximately $70.0 million. In addition, Dynavax has granted the underwriters a 30-day option to purchase up to an additional 2,100,000 shares of common stock.
Thu, 21 May 2020
20:01:10 +0000
Dynavax Technologies Announces Proposed Public Offering of Common Stock
Dynavax Technologies Corporation (DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering. Dynavax also expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the common stock being offered in the public offering. All of the shares in the offering will be sold by Dynavax.
Wed, 20 May 2020
17:18:05 +0000
Biotech Stock Roundup: MRNA, DVAX Up on Coronavirus Treatment Updates, & More
The biotech sector remains in focus with pipeline updates on coronavirus treatments.
Tue, 19 May 2020
20:08:30 +0000
7 Biotech Stocks Wall Street Says Will Double or More
Bull market or bear market, one fact remains unwavering: Biotech stocks represent the ultimate risk/reward plays.These investments are inherently volatile in nature. Numerous biotechnology companies have just one or two products delivering revenue, which means any news around new potential treatments has added urgency. That results in bigger price swings. "Pre-revenue" biotech stocks - those with no approved products - are even shakier in nature. These companies are in a race to get a treatment approved before they run out of money for research and trials.Following biotechnology companies isn't like following the rest of the market, either. In many cases, biotech earnings reports aren't a lightning rod for share-price movements. Instead, these stocks tend to ebb and flow on clinical data releases and regulatory approval decisions, which are arguably far more important metrics for gauging biotechnology firms' long-term prospects.So, how are investors supposed to distinguish between the long-term winners and those poised to take an "L"? We suggest taking a page from the analyst community's playbook.Using TipRanks' database, we were able to scan the densely populated industry for the most compelling plays. These biotech stocks not only have earned overwhelmingly bullish support from the Wall Street analysts who cover them, but sky-high upside based on the pros' estimates. Here are seven of Wall Street's best biotech stocks right now, according to the analyst community, which believes each of these picks has triple-digit return potential. SEE ALSO: Pros' Picks: The 15 Best Nasdaq Stocks You Can Buy
Tue, 19 May 2020
13:00:00 +0000
Why Dynavax Technologies Is Jumping Today
Shares of the small-cap biotech Dynavax Technologies Corporation (NASDAQ: DVAX) are poised for a big day today. Investors are bidding up Dynavax's shares this morning in anticipation of the company's COVID-19 vaccine program update, which is scheduled for later today. One of the main reasons for all the excitement is that Dynavax has already announced that one or more of its collaboration partners should initiate an early stage COVID-19 vaccine trial by July.
Tue, 19 May 2020
11:16:23 +0000
Dynavax Explodes 40% In Pre-Market On Phase 1 Covid-19 Vaccine News
Dynavax Technologies (DVAX) is surging 40% in Tuesday’s pre-market trading after revealing that it expects one or more of its collaboration partners will commence a Phase 1 clinical trial of a potential COVID-19 vaccine as soon as July 2020.According to the SEC filing, Dynavax intends to provide an update on its early-stage collaborations in meetings with analysts and investors today.It will discuss the potential development of a vaccine for COVID-19 containing the company’s proprietary toll-like receptor 9 agonist adjuvant CpG-1018 (“CpG-1018”), the adjuvant used in the company’s Heplisav-B product.Heplisav-B is indicated for prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. According to Dynavax, 95% of those who received Heplisav-B were protected after just 2 doses in 1 month.“However, there are risks and uncertainties inherent in vaccine research and development, including the timing of completing development, the results of clinical trials, whether the vaccine will be approved for use, the extent of competition, and whether a vaccine can be successfully commercialized” DVAX adds, warning that as a result, its development of a potential COVID-19 vaccine may not be successful.Indeed, HC Wainwright analyst Edward White recently reiterated his Dynavax buy rating with a $12 price target, writing “We do not include any of these COVID-19 collaborations in our valuation, but we view them as an upside option on the recent COVID-19 outbreak.”Instead, he wrote: “We base our $12 price target on our discounted revenue forecasts for Heplisav-B.” This price target indicates 147% upside potential lies ahead. The stock is currently trading down 15% on a year-to-date basis.Overall DVAX has received three recent buy ratings, adding up to a Strong Buy analyst consensus. (See Dynavax stock analysis on TipRanks).Related News: Europe Could Conditionally Approve Gilead’s Remdesivir In Next Few Days Moderna Spikes 21% Amid “Positive” Early-Stage Covid-19 Vaccine Data AstraZeneca Aiming For 30M UK Covid-19 Vaccine Doses By September More recent articles from Smarter Analyst: * Tilray To Shut Ontario Cannabis Greenhouse In Money-Saving Move * Here’s Why Roku Stock Will Stay Afloat * Is CymaBay’s Seladelpar Back in the Saddle? 5-Star Analyst Weighs In * Why Aurora Cannabis (ACB) Stock Looks Attractive
Thu, 14 May 2020
13:24:01 +0000
Why Dynavax Technologies (DVAX) Stock Might be a Great Pick
Dynavax Technologies (DVAX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Sat, 09 May 2020
18:31:01 +0000
Dynavax Technologies Corp (DVAX) Q1 2020 Earnings Call Transcript
Joining me on the call today are Ryan Spencer, Chief Executive Officer; Michael Ostrach, Chief Financial Officer; Donn Casale, Vice President, Commercial. Before we begin, I advise you that we will be making forward-looking statements today, including statements regarding HEPLISAV-B's commercial profile, revenue expectations, potential peak revenue, the completion of post-marketing studies and regarding vaccine development with CpG-1018.
Thu, 07 May 2020
20:10:10 +0000
Dynavax Announces First Quarter 2020 Financial Results
Q1 2020 HEPLISAV-B® net product revenue of $10.5 million, compared to $5.6 million in Q1 2019Multiple collaborations established leveraging Dynavax’s vaccine adjuvant CpG 1018.
Tue, 28 Apr 2020
20:10:10 +0000
Dynavax Reports Interim Analysis of Ongoing Clinical Trial Evaluating HEPLISAV-B in Patients Undergoing Hemodialysis
Demonstrated seroprotection rate of 86.4% at week 20 after 4 standard doses of HEPLISAV-BSafety data showed HEPLISAV-B was well toleratedCompany to host webinar review of data.
Thu, 23 Apr 2020
20:10:10 +0000
Dynavax to Report First Quarter 2020 Financial Results and Host Conference Call on May 7, 2020
EMERYVILLE, Calif., April 23, 2020 -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines,.



"ValueForum is an active, private, online discussion community for stock & bond market investing. In discussion forums divided into finely grained topics, you will find sophisticated investors trading tips, research, and due diligence on value stocks, income investments, forex, market news, and more. Join in - trade ideas, strategies, current news, via our unique message bulletin boards, stock ratings system, and other online tools specifically geared toward our community."

Random member testimonial: "This is one of the brightest and most generous groups you will ever come across. While I firmly believe everyone has something to contribute to the collective wisdom, this is pretty much a left-brain group. Facts, evidence, and reasoned argument will earn you respect, even if some disagree with you." more testimonials »

Email / About | Privacy | Terms of Use | How To / FAQ | Msg Ticker | VF Home | My.vf | BDCs.vf | Energy.vf | REITs.vf | TA.vf
 
Nothing in ValueForum.com is intended to be investment advice, nor does it represent the opinion of, counsel
from, or recommendations by ValueForum.com. ©2003 - 2020, Powered in part by Ticker TechnologiesContact Us

Stock Market Investing Forum - Trading Tips & Research - Online Message Boards